Dec 1, 2022 7:00am EST Tonix Pharmaceuticals Presents Development Update on Potential Smallpox and Monkeypox Vaccine TNX-801 in an Oral Presentation at the World Vaccine and Immunotherapy Congress
Nov 30, 2022 7:00am EST Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral Congress
Nov 22, 2022 7:00am EST Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine and Immunotherapy Congress
Nov 21, 2022 7:00am EST Tonix Pharmaceuticals Announces Oral Presentation at the World Antiviral Congress
Nov 16, 2022 7:00am EST Tonix Pharmaceuticals Announces Data from an in vitro Study of the Impact of Oxytocin on Human Neurons at Neuroscience 2022, the Annual Meeting of the Society for Neuroscience
Nov 9, 2022 7:00am EST Tonix Pharmaceuticals Announces Poster Presentation at Neuroscience 2022 by the Society for Neuroscience
Nov 7, 2022 7:00am EST Tonix Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
Oct 25, 2022 7:00am EDT Tonix Pharmaceuticals Announces Pricing of $15 Million Private Placement of Convertible Redeemable Preferred Stock
